1results about How to "Dose-dependent improvement" patented technology

This invention relates to the application of (E)-2-(4-(dimethylamino)styryl)-6-methoxy-3-methylbenzo[d]thiazol-3-onthium in the preparation of anticancer drugs, belonging to the field of pharmaceutical technology. The structure of (E)-2-(4-(dimethylamino)styryl)-6-methoxy-3-methylbenzo[d]thiazol-3-onthium is shown in Formula I below. The (E)-2-(4-(dimethylamino)styryl)-6-methoxy-3-methylbenzo[d]thiazol-3-onthium of this invention can inhibit the growth of gastric cancer cells. By promoting autophagy and mitochondrial fragmentation in gastric cancer cells AGS and HGC-27, it inhibits the proliferation, invasion, and migration of gastric cancer cells and arrests them in the G1 phase. Furthermore, in vivo experiments in mice have confirmed that ZWK-3 can inhibit tumor growth in mice in a significant dose-dependent manner, without affecting mouse body weight or visceral indices. Formula I.